H.R. 6572

119 HR 6572 IH: Launching X–Labs for Breakthrough Science Act
 U.S. House of Representatives
 2025-12-10
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 I  119th CONGRESS  1st Session  H. R. 6572  IN THE HOUSE OF REPRESENTATIVES   December 10, 2025   Mr. Harder of California  (for himself and  Mr. Obernolte ) introduced the following bill; which was referred to the  Committee on Energy and Commerce    A BILL
To direct the Director of the National Institutes of Health to carry
  out a program, to be known as the  X-Labs Initiative , to support
  breakthrough biomedical research at innovative research institutions, and for other
 purposes.
1.
Short title
This Act may be cited as the   Launching X–Labs for Breakthrough Science Act  .
2.
NIH institutional awards for breakthrough biomedical research
Part A of title IV of the Public Health Service Act ( 42 U.S.C. 281 et seq. ) is amended by adding at the end the following:
404P.
NIH institutional awards for breakthrough biomedical research
(a)
In general
The Director of NIH shall establish a program, to be known as the  X–Labs Initiative , to provide long-term institutional awards to eligible entities in accordance with the requirements of this section.
(b)
Purposes
The purposes of the program shall be—
(1)
to enable and catalyze innovative research institutions to conduct breakthrough biomedical research; and
(2)
to assist such institutions in the acquisition of R&D plant, as necessary, to complete such research.
(c)
Institutional awards
(1)
In general
In carrying out the program, the Director of NIH shall, acting directly or through the head of an NIH institute or center, make institutional awards to eligible entities on a competitive basis.
(2)
XL‑series activity code
The Director of NIH shall designate the  XL‑series  as a distinct NIH activity code available to all NIH institutes and centers making institutional awards under the program.
(3)
Categories
An institutional award under the program shall be made within one of the following categories:
(A)
XL01 funding
Awards of XL01 funding to support basic science research institutions whose principal activities, or proposed principal activities, are directed toward advancing foundational scientific discovery. The purpose of such awards shall be to provide such institutions stable, long-term funding and minimal budgetary reprogramming requirements.
(B)
XL02 funding
Awards of XL02 funding to support science institutions whose principal activities, or proposed principal activities, are directed toward developing new scientific resources, including datasets or measurement tools or techniques, with deliverables that are clearly defined at the beginning of the award.
(C)
XL03 funding
Awards of XL03 funding to support nonprofit institutions that award focused research organizations, individual researchers, or research collaborations or centers funds to conduct breakthrough biomedical research.
(D)
XL04 funding
Awards of XL04 funding to support the formation and planning of new scientific institutions that will be eligible for XL01, XL02, or XL03 funding.
(4)
Special rules applicable to XL03 funding
(A)
Regrants
An eligible entity that receives an award of XL03 funding described in paragraph (3)(C) shall, subject to the terms of the award, make regrants using funds from the award to support research teams, early-stage projects, or innovative scientific initiatives consistent with the purposes of this section. Such teams, projects, and initiatives shall be located in the United States.
(B)
Requirements
An eligible entity that receives an award of XL03 funding described in paragraph (3)(C)—
(i)
shall use such funding to provide assistance, through regrants described in subparagraph (A), to organizations (in this section referred to as  regrant recipients ) that the eligible entity determines are unlikely to receive support through traditional NIH grants despite the breakthrough potential of the research to be conducted by the regrant recipient;
(ii)
shall use innovative methods to identify, fund, and evaluate the research to be conducted using such assistance; and
(iii)
not later than one year after the date on which the eligible entity provides such assistance to a regrant recipient, shall make available to the public a summary of the method by which the eligible entity identified, funded, and plans to evaluate the regrant recipient.
(5)
Amounts
(A)
XL01, XL02, and XL03 funding
(i)
In general
The Director of NIH shall structure an award of XL01, XL02, or XL03 funding such that the award totals not less than $5,000,000 and not more than $50,000,000 per fiscal year for a period of 7 consecutive fiscal years. The amount of such an award shall be determined based on institutional scope, scientific ambition, and programmatic needs.
(ii)
Renewals
The Director of NIH may renew an award described in clause (i) for not more than one additional period of 7 consecutive fiscal years, subject to—
(I)
a competitive review of institutional performance and scientific impact over the previous period;
(II)
the availability of appropriations; and
(III)
a programmatic cap on the proportion of institutional awards eligible for renewal, to be determined by the Director of NIH, to ensure regular entry of new institutions into the program.
(B)
XL04 funding
(i)
In general
The Director of NIH shall structure an award of XL04 funding such that the award totals not less than $1,000,000 and not more than $5,000,000 per fiscal year for a period of 1, 2, or 3 consecutive fiscal years, as determined by the Director of NIH.
(ii)
Prohibition on renewals
The Director of NIH may not renew an award described in clause (i).
(6)
Applications
An eligible entity seeking an award under the program shall submit to the Director of NIH an application at such time, in such form, and containing such information as the Director of NIH may require.
(7)
Maintaining eligibility
To remain eligible for an institutional award under the program and remain in good standing with respect to an award, an eligible entity shall not compete for or receive any other Federal research funding in the form of a research grant, excluding a training grant, during the award period of the entity for XL01, XL02, or XL03 funding.
(8)
Early termination or suspension
(A)
In general
The Director of NIH may terminate or suspend an award made to an award recipient under this section prior to the expiration of the applicable period of the award described in paragraph (5) if the Director determines that the award recipient—
(i)
is not meeting the deliverables referred to in paragraph (3)(B), if applicable;
(ii)
is no longer an eligible entity; or
(iii)
is otherwise failing to comply with the terms and conditions of the award.
(B)
Revocation of funds; reallocation
Upon a determination to terminate or suspend an award under subparagraph (A), the Director of NIH may revoke any remaining funds from the award and reallocate such funds to new awards under this section.
(d)
Administration
(1)
In general
The program shall be administered by the Director of NIH, in coordination with the heads of relevant institutes and centers.
(2)
Institute participation
Any institute or center within the National Institutes of Health may utilize the program to fund institutions within their areas of scientific focus, subject to coordination with the Director of NIH and the availability of funds.
(3)
Other transactions authorities
Notwithstanding any other provision of law, the Director of NIH may use the authorities available under section 402(n)(1) or other applicable transactions authorities to carry out this section.
(e)
Reporting requirements
(1)
Initial reports
Not later than 1 year after the date of enactment of this Act, and annually thereafter for 2 additional years, the Director of NIH shall submit to the appropriate committees of Congress a report describing—
(A)
the progress made in establishing the program, including the development of application processes, review criteria, and award categories;
(B)
the number and types of applications received under the program;
(C)
the number, type, and amount of awards made under the program; and
(D)
any challenges or barriers encountered in the implementation of the program.
(2)
Periodic evaluation
Not later than 5 years after the date of the first award under the program, and once every 5 years thereafter during the term of the program, the Director of NIH shall submit to the appropriate committees of Congress a report evaluating—
(A)
the scientific impact and outcomes of institutions receiving support under the program;
(B)
the effectiveness of the program in advancing the purposes described in subsection (b);
(C)
lessons learned from implementation of the program and recommendations for program improvement; and
(D)
the extent to which the program has reduced administrative burden and enabled research that is high-risk and high-reward.
(f)
Definitions
In this section:
(1)
Appropriate committees of Congress
The term  appropriate committees of Congress  means—
(A)
the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives; and
(B)
the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate.
(2)
Basic science research institution
The term  basic science research institution  means a research institution conducting systematic study directed toward greater understanding of fundamental principles or phenomena of nature without specific applications in mind.
(3)
Breakthrough biomedical research
The term  breakthrough biomedical research  means scientific research that has the potential to create substantial, field-defining advances in knowledge, methods, or technologies that enable significant improvements in human health or scientific capability.
(4)
Eligible entity
The term  eligible entity  means—
(A)
a nonprofit research organization;
(B)
an institution of higher education, as defined in section 101 of the Higher Education Act of 1965;
(C)
a for-profit entity with nonprofit subsidiaries dedicated to scientific research;
(D)
an individual with plans to establish a nonprofit research organization; or
(E)
any other research organization that the Director of NIH determines appropriate.
(5)
Focused research organization
The term  focused research organization  means a time-limited, goal-oriented nonprofit entity that concentrates resources and talent on achieving a defined scientific or technological objective not sufficiently pursued within existing academic, corporate, or government structures.
(6)
Foundational scientific discovery
The term  foundational scientific discovery  means research that produces broadly enabling scientific knowledge, methods, or tools that support subsequent applied or translational advances.
(7)
Institutional award; award
The term  institutional award  or  award  means an award of funding made under the program.
(8)
Institutional scope
The term  institutional scope  means the size and organizational capacity of an institution to undertake research activities, including the breadth of its scientific research, number of personnel supported, and physical research infrastructure relevant to the proposed award.
(9)
NIH
The term  NIH  means the National Institutes of Health.
(10)
Nonprofit research organization
The term  nonprofit research organization  means a domestic public or private organization exempt from taxation under  section 501(c)(3)  of the Internal Revenue Code of 1986 that conducts or supports scientific research as a primary purpose.
(11)
Program
The term  program  means the program authorized under subsection (a).
(12)
Programmatic needs
The term  programmatic needs  means the degree to which an award would advance the strategic research priorities and unmet needs of NIH and its institutes and centers, as determined by the Director of NIH.
(13)
R&D plant
The term  R&D plant  means fixed assets used primarily for research and development, including the construction, expansion, leasing, or modernization of research facilities and the acquisition of major movable research equipment.
(14)
Regrant
The term  regrant  means the provision of a subaward or other financial assistance by an award recipient under the program to carry out research activities consistent with the purposes of the original award.
(15)
Scientific ambition
The term  scientific ambition  means the scale, novelty, and transformative potential of an institution’s proposed research agenda under an award, as measured by the significance of the scientific questions addressed and the potential to advance fundamental or translational understanding.
(16)
United States
The term  United States  means the States and the District of Columbia.
(g)
Authorization of appropriations
There is authorized to be appropriated to carry out this section such sums as may be necessary for each of fiscal years 2026 through 2031.
 .